Abemaciclib and diarrhea in high-risk hormone positive breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study looks at how the body handles the drug abemaciclib, and how it relates to severe diarrhea, which is a common side effect. It is for people with high-risk, hormone receptor positive breast cancer who have already had surgery. The goal is to better understand and possibly manage diarrhea, so you can stay on treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have hormone receptor positive (HR+) and HER2 negative or low breast cancer, stage 2 or 3.
- Your cancer is considered high risk of coming back (for example, it spread to 4 or more lymph nodes, or fewer nodes with a high grade or large tumor).
- You have had surgery to remove the tumor completely, with or without chemotherapy before.
- You are about to start or have just started abemaciclib with hormone therapy.
- You have not taken a CDK4/6 inhibitor before, and you do not have chronic bowel disease causing diarrhea.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how gut bacteria changes in people taking Abemaciclib (a breast cancer drug) and whether that relates to diarrhea. It may help find ways to prevent or manage this side effect.
This study tests whether women with early-stage HR+/HER2- breast cancer can safely take a higher dose of the drug abemaciclib (Verzenio) after surgery. The goal is to keep the treatment as strong as possible while managing side effects.
This trial tests whether a targeted therapy (abemaciclib) combined with focused radiation (SBRT) to a bone tumor can help people with advanced breast cancer. It is for patients whose cancer is hormone receptor positive and HER2 negative, and who will continue abemaciclib after radiation.
This trial tests a drug called abemaciclib for people with early-stage, hormone-receptor-positive, HER2-negative breast cancer who still have cancer DNA in their blood after completing standard treatment. It aims to see if taking this drug can reduce the chance of cancer coming back.
This study looks at how the bacteria in your digestive system may affect side effects from abemaciclib, a hormone-based breast cancer drug. By collecting stool samples, researchers hope to understand which patients might experience fewer problems and how to better manage treatment.
This trial studies how the immune system and other body signals in blood and tumor tissue relate to how well abemaciclib works before breast cancer surgery. The goal is to learn who benefits most from this medicine and why.
Hear when a new Abemaciclib trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.